Cardiorenal effects of newer NSAIDs (celecoxib) versus classic NSAIDs (ibuprofen) in patients with arthritis

Journal of Toxicology

Volumn 2011, Issue , 2011, Pages

  Hegazy, Ragia ^a,b   Alashhab, Mohamed ^a   Amin, Madiha ^b,c  

^a BENHA UNIVERSITY   (Egypt)

^b UMM AL QURA UNIVERSITY   (Saudi Arabia)

^c Alexandria University Faculty of Pharmacy   (Egypt)

Author keywords

[No Author keywords available]

Indexed keywords

CELECOXIB; CREATININE; ELECTROLYTE; IBUPROFEN;

ACID BASE BALANCE; ADULT; AGED; ARTHRITIS; ARTICLE; BLOOD PRESSURE; BODY WEIGHT; CARDIOTOXICITY; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DRUG EFFECT; DRUG WITHDRAWAL; EDEMA; ELECTROLYTE BLOOD LEVEL; FLUID RETENTION; HUMAN; HYPERTENSION; HYPONATREMIA; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; SIDE EFFECT; SYSTOLIC HYPERTENSION; UREMIA;

EID: 80052648563     PISSN: 16878191     EISSN: 16878205     Source Type: Journal    
DOI: 10.1155/2011/862153     Document Type: Article

References (34)

1. Skelly M. M., Hawkey C. J., Dual COX inhibition and upper gastrointestinal damage Current Pharmaceutical Design 2003 9 27 2191 2195 (Pubitemid 37139093)
2. FitzGerald G. A., COX-2 and beyond: approaches to prostaglandin inhibition in human disease Nature Reviews Drug Discovery 2003 2 11 879 890
3. Gabriel S. E., Jaakkimainen L., Bombardier C., Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs. A meta-analysis Annals of Internal Medicine 1991 115 10 787 796
4. Riendeau D., Percival M. D., Brideau C., Charleson S., Dubé D., Ethier D., Falgueyret J. P., Friesen R. W., Gordon R., Greig G., Guay J., Mancini J., Ouellet M., Wong E., Xu L., Boyce S., Visco D., Girard Y., Prasit P., Zamboni R., Rodger I. W., Gresser M., Ford-Hutchinson A. W., Young R. N., Chan C. C., Etoricoxib (MK-0663): preclinical profile and comparison with other agents that selectively inhibit cyclooxygenase-2 Journal of Pharmacology and Experimental Therapeutics 2001 296 2 558 566 (Pubitemid 32112486)
5. Brune K., Hinz B., Selective cyclooxygenase-2 inhibitors: similarities and differences Scandinavian Journal of Rheumatology 2004 33 1 1 6 (Pubitemid 38328075)
6. Fitzpatrick F. A., Cyclooxygenase enzymes: regulation and function Current Pharmaceutical Design 2004 10 6 577 588 (Pubitemid 38292385)
7. Simon L. S., Nonsteroidal antiinflammatory drugs and their effects Journal of Clinical Rheumatology 1996 2 3 135 140
8. Whelton A., Maurath C. J., Verburg K. M., Geis G. S., Renal safety and tolerability of celecoxib, a novel cyclooxygenase-2 inhibitor American Journal of Therapeutics 2000 7 3 159 175
9. Harris R. C. Jr., Cyclooxygenase-2 inhibition and renal physiology American Journal of Cardiology 2002 89 6 10D 17D (Pubitemid 34241483)
10. Silverstein F. E., Faich G., Goldstein J. L., Gastrointestinal toxicity with celecoxib vs non steroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study Journal of the American Medical Association 2000 284 1247 1255
11. Patton C. J., Crouch S. R., Enzymatic determination of serum urea Analytical Chemistry 1977 49 464 469
12. Henry R. J., Clinical chemistry Principles and Techniques of Chemical Analysis 1974 2nd Oxford, UK Harper and Row, Pergman Press 525 540
13. Daniel P., Biostatistics: A Foundation for Analysis in the Health Sciences 1995 6th New York, NY, USA John Wiley and Sons
14. Dogne J. M., Hanson J., Supuran C., Pratico D., Coxibs and cardiovascular side-effects: from lights to shadow Current Pharmaceutical Design 2006 12 8 971 975
15. ALLAHT Officers and Coordinators for the ALLAHT Collaborative Research Group, The antihypertensive and lipid lowering treatment to prevent heart attack trial. Major outcomes in high risk hypertensive patients randomized to ACE inhibitors or calcium channel blockers vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLAHT) Journal of the American Medical Association 2002 288 23 2981 2997
16. Kostis J. B., Davis B. R., Cutler J., Prevention of heart failure by antihypertensive drug treatment in older persons with isolated systolic hypertension. SHEP Cooperative Research Group Journal of the American Medical Association 1997 278 3 212 216 (Pubitemid 27339586)
17. Steassen J. A., Fagard R., Thijis L., Randomized double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension The Lancet 1997 350 757 764 (Pubitemid 27387202)
18. Whelton A., Spalding E., White W. B., Rofecoxib increases cardiovascular events in arthritis patients but celecoxib and non specific non steroidal anti-inflammatory drugs do not Journal of the American College of Cardiology 2004 5 supplement 415 443
19. Whelton A., The coxib conundrum: lessons from the rise and fall of rofecoxib American Journal of Therapeutics 2004 11 6 417 421
20. Whelton A., Fort J. G., Puma J. A., Normandin D., Bello A. E., Verburg K. M., SUCCESS VI Study Group, Cyclooxygenase-2specific inhibitors and cardiorenal function: a randomized, controlled trial of celecoxib and rofecoxib in older hypertensive osteoarthritis patients American Journal of Therapeutics 2001 8 2 85 95 (Pubitemid 33753522)
21. White W. B., Kent J., Taylor A., Verburg K. M., Lefkowith J. B., Whelton A., Effects of celecoxib on ambulatory blood pressure in hypertensive patients on ACE inhibitors Hypertension 2002 39 4 929 934 (Pubitemid 34437552)
22. De Leeuw P. W., Non-steroidal anti-inflammatory drugs affect blood pressure? A meta analysis Annals of Internal Medicine 1996 121 289 300
23. Catella-Lawson F., Mcadam B., Morrison B. W., Kapoor S., Kujubu D., Antes L., Lasseter K. C., Quan H., Gertz B. J., FitzGerald G. A., Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids Journal of Pharmacology and Experimental Therapeutics 1999 289 2 735 741 (Pubitemid 29191226)
24. Svendsen K. B., Bech J. N., Sorensen T. B., Pedersen E. B., A comparison of the effects of etodolac and ibuprofen on renal haemodynamics, tubular function, renin, vasopressin and urinary excretion of albumin and alpha-glutathione-S-transferase in healthy subjects: a placebo-controlled cross over study European Journal of Clinical Pharmacology 2000 56 5 383 388 (Pubitemid 30666064)
25. Rossat J., Maillard M., Nussberger J., Brunner H. R., Burnier M., Renal effects of selective cyclooxygenase-2 inhibition in normotensive salt-depleted subjects Clinical Pharmacology and Therapeutics 1999 66 1 76 84 (Pubitemid 29350448)
26. Swan S. K., Rudy D. W., Lasseter K. C., Ryan C. F., Buechel K. L., Lambrecht L. J., Pinto M. B., Dilzer S. C., Obrda O., Sundblad K. J., Gumbs C. P., Ebel D. L., Quan H., Larson P. J., Schwartz J. I., Musliner T. A., Gertz B. J., Brater D. C., Yao S. L., Effect of cyclooxygenase-2 inhibition on renal function in elderly persons receiving a low-salt diet. A randomized, controlled trial Annals of Internal Medicine 2000 133 1 1 9 (Pubitemid 30432538)
27. Whelton A., Schulman G., Wallemark C., Drower E. J., Isakson P. C., Verburg K. M., Geis G. S., Effects of celecoxib and naproxen on renal function in the elderly Archives of Internal Medicine 2000 160 10 1465 1470 (Pubitemid 30327449)
28. Cheng H. F., Wang J. L., Zhang M. Z., McKanna J. A., Harris R. C., Nitric oxide regulates renal cortical cyclooxygenase-2 expression American Journal of Physiology 2000 279 1 F122 F129 (Pubitemid 30619553)
29. Lpez R., Roig F., Llins M. T., Salazar F. J., Role of cyclooxygenase-2 in the control of renal haemodynamics and excretory function Acta Physiologica Scandinavica 2003 177 4 429 435 (Pubitemid 36411580)
30. Jni P., Nartey L., Reichenbach S., Sterchi R., Dieppe P. A., Egger M., Risk of cardiovascular events and rofecoxib: cumulative meta-analysis The Lancet 2004 364 9450 2021 2029 (Pubitemid 39593078)
31. Aisen P. S., Schafer K., Grundman M., Thomas R., Thal L. J., NSAIDs and hypertension Archives of Internal Medicine 2003 163 9 1115 1116
32. Whelton A., White W. B., Bello A. E., Puma J. A., Fort J. G., Effects of celecoxib and rofecoxib on blood pressure and edema in patients above 65 years of age with systemic hypertension and osteoarthritis American Journal of Cardiology 2002 90 9 959 963 (Pubitemid 35232619)
33. Izhar M., Alausa T., Folker A., Hung E., Bakris G. L., Effects of COX inhibition on blood pressure and kidney function in ACE inhibitor-treated blacks and hispanics Hypertension 2004 43 3 573 577 (Pubitemid 38282430)
34. Whelton A., Lefkowith J., West C., Verburg K., Cardiorenal effects of coxib as compared with non selective non steroidal anti-inflammatory drugs Kidney International 2006 70 1495 1502 (Pubitemid 44527321)